Boston Scientific (NYSE:BSX) and Fielmann Group (OTCMKTS:FLMNY) Critical Analysis

Fielmann Group (OTCMKTS:FLMNY) and Boston Scientific (NYSE:BSX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares Fielmann Group and Boston Scientific”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fielmann Group	N/A	N/A	N/A	$0.37	24.80
Boston Scientific	$20.07 billion	3.56	$2.90 billion	$2.47	19.98

Boston Scientific has higher revenue and earnings than Fielmann Group. Boston Scientific is trading at a lower price-to-earnings ratio than Fielmann Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.1% of Boston Scientific shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Fielmann Group and Boston Scientific, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fielmann Group	0	0	0	0	0.00
Boston Scientific	2	5	24	0	2.71

Boston Scientific has a consensus target price of $71.62, suggesting a potential upside of 45.11%. Given Boston Scientific’s stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Fielmann Group.

Profitability

This table compares Fielmann Group and Boston Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fielmann Group	N/A	N/A	N/A
Boston Scientific	17.50%	19.28%	10.89%

Summary

Boston Scientific beats Fielmann Group on 10 of the 11 factors compared between the two stocks.

About Fielmann Group

Fielmann Group AG provides optical and hearing aid services in Germany, Switzerland, Austria, and internationally. It manufactures and sells visual aids mainly glasses, frames, lenses, sunglasses, contact lenses, accessories, hearing aids systems and its accessories, as well as personal protective equipment. The company offers its products under the fielmann, Optika Clarus, OPTICA & AUDIOLOGIA UNIVERSITARIA, Medical optica audicion, and SVS VISION brand names. It sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform. The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is headquartered in Hamburg, Germany. The company is a subsidiary of Korva SE.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.